APO RESEARCH · REPORT
Viral Vectors and Plasmid DNA Manufacturing
The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.
Product & engineering
Understand the product.
The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.
Selected research
Industry Research
Viral Vectors and Plasmid DNA Manufacturing Industry Research Report 2026
Market perspective
The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.
Global Viral Vectors and Plasmid DNA Manufacturing key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific, and Europe, both have a share over 40 percent.
Read the full market overview
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections , etc.
Report Scope
This report quantifies the global Viral Vectors and Plasmid DNA Manufacturing market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Viral Vectors and Plasmid DNA Manufacturing.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Viral Vectors and Plasmid DNA Manufacturing Market by Company
BioReliance
Cobra Biologics
Oxford BioMedica
UniQure
FinVector
MolMed
MassBiologics
Richter-Helm
FUJIFILM Diosynth Biotechnologies
Lonza
Aldevron
Eurogentec
Cell and Gene Therapy Catapult
Biovian
Thermo Fisher Scientific (Brammer Bio)
VGXI
PlasmidFactory
Viral Vectors and Plasmid DNA Manufacturing Segment by Type
Plasmid DNA
Viral Vectors
Viral Vectors and Plasmid DNA Manufacturing Segment by Application
Cancers
Inherited Disorders
Viral Infections
Others
Viral Vectors and Plasmid DNA Manufacturing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vectors and Plasmid DNA Manufacturing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viral Vectors and Plasmid DNA Manufacturing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vectors and Plasmid DNA Manufacturing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Viral Vectors and Plasmid DNA Manufacturing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Plasmid DNA
- Viral Vectors
Applications
- Cancers
- Inherited Disorders
- Viral Infections
- Others
Companies covered
- BioReliance
- Cobra Biologics
- Oxford BioMedica
- UniQure
- FinVector
- MolMed
- MassBiologics
- Richter-Helm
- FUJIFILM Diosynth Biotechnologies
- Lonza
- Aldevron
- Eurogentec
- Cell and Gene Therapy Catapult
- Biovian
- Thermo Fisher Scientific (Brammer Bio)
- VGXI
- PlasmidFactory
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Viral Vectors and Plasmid DNA Manufacturing by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Plasmid DNA
- 2.2.3 Viral Vectors
- 2.3 Viral Vectors and Plasmid DNA Manufacturing by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancers
- 2.3.3 Inherited Disorders
- 2.3.4 Viral Infections
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Viral Vectors and Plasmid DNA Manufacturing Breakdown Data by Type
- 3.1 Global Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by Type (2021-2026)
- 3.2 Global Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Type (2027-2032)
4 Viral Vectors and Plasmid DNA Manufacturing Breakdown Data by Application
- 4.1 Global Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by Application (2021-2026)
- 4.2 Global Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Perspective (2021-2032)
- 5.2 Global Viral Vectors and Plasmid DNA Manufacturing Growth Trends by Region
- 5.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by Region (2021-2026)
- 5.2.3 Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Region (2027-2032)
- 5.3 Viral Vectors and Plasmid DNA Manufacturing Market Dynamics
- 5.3.1 Viral Vectors and Plasmid DNA Manufacturing Industry Trends
- 5.3.2 Viral Vectors and Plasmid DNA Manufacturing Market Drivers
- 5.3.3 Viral Vectors and Plasmid DNA Manufacturing Market Challenges
- 5.3.4 Viral Vectors and Plasmid DNA Manufacturing Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Viral Vectors and Plasmid DNA Manufacturing Players by Revenue
- 6.1.1 Global Top Viral Vectors and Plasmid DNA Manufacturing Players by Revenue (2021-2026)
- 6.1.2 Global Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Players (2021-2026)
- 6.2 Global Viral Vectors and Plasmid DNA Manufacturing Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Viral Vectors and Plasmid DNA Manufacturing Head Office and Area Served
- 6.4 Global Viral Vectors and Plasmid DNA Manufacturing Players, Product Type & Application
- 6.5 Global Viral Vectors and Plasmid DNA Manufacturing Manufacturers Established Date
- 6.6 Global Viral Vectors and Plasmid DNA Manufacturing Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Viral Vectors and Plasmid DNA Manufacturing Market Size (2021-2032)
- 7.2 North America Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2021-2026)
- 7.4 North America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size (2021-2032)
- 8.2 Europe Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2021-2026)
- 8.4 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size (2021-2032)
- 9.2 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Viral Vectors and Plasmid DNA Manufacturing Market Size (2021-2032)
- 10.2 South America Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2021-2026)
- 10.4 South America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size (2021-2032)
- 11.2 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 BioReliance
- 12.1.1 BioReliance Company Information
- 12.1.2 BioReliance Business Overview
- 12.1.3 BioReliance Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.1.4 BioReliance Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.1.5 BioReliance Recent Developments
- 12.2 Cobra Biologics
- 12.2.1 Cobra Biologics Company Information
- 12.2.2 Cobra Biologics Business Overview
- 12.2.3 Cobra Biologics Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.2.4 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.2.5 Cobra Biologics Recent Developments
- 12.3 Oxford BioMedica
- 12.3.1 Oxford BioMedica Company Information
- 12.3.2 Oxford BioMedica Business Overview
- 12.3.3 Oxford BioMedica Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.3.4 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.3.5 Oxford BioMedica Recent Developments
- 12.4 UniQure
- 12.4.1 UniQure Company Information
- 12.4.2 UniQure Business Overview
- 12.4.3 UniQure Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.4.4 UniQure Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.4.5 UniQure Recent Developments
- 12.5 FinVector
- 12.5.1 FinVector Company Information
- 12.5.2 FinVector Business Overview
- 12.5.3 FinVector Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.5.4 FinVector Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.5.5 FinVector Recent Developments
- 12.6 MolMed
- 12.6.1 MolMed Company Information
- 12.6.2 MolMed Business Overview
- 12.6.3 MolMed Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.6.4 MolMed Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.6.5 MolMed Recent Developments
- 12.7 MassBiologics
- 12.7.1 MassBiologics Company Information
- 12.7.2 MassBiologics Business Overview
- 12.7.3 MassBiologics Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.7.4 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.7.5 MassBiologics Recent Developments
- 12.8 Richter-Helm
- 12.8.1 Richter-Helm Company Information
- 12.8.2 Richter-Helm Business Overview
- 12.8.3 Richter-Helm Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.8.4 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.8.5 Richter-Helm Recent Developments
- 12.9 FUJIFILM Diosynth Biotechnologies
- 12.9.1 FUJIFILM Diosynth Biotechnologies Company Information
- 12.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
- 12.9.3 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.9.4 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
- 12.10 Lonza
- 12.10.1 Lonza Company Information
- 12.10.2 Lonza Business Overview
- 12.10.3 Lonza Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.10.4 Lonza Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.10.5 Lonza Recent Developments
- 12.11 Aldevron
- 12.11.1 Aldevron Company Information
- 12.11.2 Aldevron Business Overview
- 12.11.3 Aldevron Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.11.4 Aldevron Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.11.5 Aldevron Recent Developments
- 12.12 Eurogentec
- 12.12.1 Eurogentec Company Information
- 12.12.2 Eurogentec Business Overview
- 12.12.3 Eurogentec Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.12.4 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.12.5 Eurogentec Recent Developments
- 12.13 Cell and Gene Therapy Catapult
- 12.13.1 Cell and Gene Therapy Catapult Company Information
- 12.13.2 Cell and Gene Therapy Catapult Business Overview
- 12.13.3 Cell and Gene Therapy Catapult Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.13.4 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.13.5 Cell and Gene Therapy Catapult Recent Developments
- 12.14 Biovian
- 12.14.1 Biovian Company Information
- 12.14.2 Biovian Business Overview
- 12.14.3 Biovian Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.14.4 Biovian Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.14.5 Biovian Recent Developments
- 12.15 Thermo Fisher Scientific (Brammer Bio)
- 12.15.1 Thermo Fisher Scientific (Brammer Bio) Company Information
- 12.15.2 Thermo Fisher Scientific (Brammer Bio) Business Overview
- 12.15.3 Thermo Fisher Scientific (Brammer Bio) Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.15.4 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.15.5 Thermo Fisher Scientific (Brammer Bio) Recent Developments
- 12.16 VGXI
- 12.16.1 VGXI Company Information
- 12.16.2 VGXI Business Overview
- 12.16.3 VGXI Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.16.4 VGXI Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.16.5 VGXI Recent Developments
- 12.17 PlasmidFactory
- 12.17.1 PlasmidFactory Company Information
- 12.17.2 PlasmidFactory Business Overview
- 12.17.3 PlasmidFactory Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2021-2026)
- 12.17.4 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.17.5 PlasmidFactory Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst